Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis

References

• Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel). 2021 Jan 30;9(1):5. doi:10.3390/medsci9010005
   PubMedGoogle Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 Sep;15(9):450–454. doi:10.1016/0167-5699(94)90276-3.
   PubMedGoogle Scholar
• Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017 Oct;34(10):2232–2273. doi:10.1007/s12325-017-0612-x.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021 Mar 4;384(9):842–858. doi:10.1056/NEJMra2027612.
   PubMed Web of Science ®Google Scholar
• Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019 Dec 12;5(1):83), doi:10.1038/s41572-019-0132-x.
   PubMed Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017 Oct;34(10):2210–2231. doi:10.1007/s12325-017-0610-z.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2019.
   Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003 Sep;73(9):712–716. doi:10.1046/j.1445-2197.2003.02748.x.
   PubMed Web of Science ®Google Scholar
• Wang P X, Li H T, Liu J M. Meta-analysis of non-comparative binary outcomes and its solution by Stata. J Evid Based Med. 2012;12:52–56.
   Google Scholar
• García-Muñoz R, Quero C, Pérez-Persona E, et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. 2020 Mar;188(5):661–673. doi:10.1111/bjh.16227.
   PubMed Web of Science ®Google Scholar
• Petrini M, Gaidano G, Mengarelli A, et al. Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from an Italian phase IIIb study. Adv Hematol. 2022 Jan 27;2022:5581772. doi:10.1155/2022/5581772.
   PubMedGoogle Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20 + diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017 Apr 1;28(4):836–842. doi:10.1093/annonc/mdw685.
   PubMed Web of Science ®Google Scholar
• Dürig J, Uhlig J, Gerhardt A, et al. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: final results of the non-interventional study MabSCale. Cancer Med. 2022 Aug 26. doi:10.1002/cam4.5160.
   PubMed Web of Science ®Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014 Jun 10;32(17):1782–1791. doi:10.1200/JCO.2013.52.2631.
   PubMed Web of Science ®Google Scholar
• Rule S, Barreto WG, Briones J, et al. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. Haematologica. 2022 Feb 1;107(2):500–509. doi:10.3324/haematol.2020.274803.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913–1922. doi:10.3324/haematol.2017.173583.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272–e282. doi:10.1016/S2352-3026(17)30078-9.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Mar;15(3):343–352. doi:10.1016/S1470-2045(14)70005-1
   PubMed Web of Science ®Google Scholar
• Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007 Jul;4(4):427–440. doi:10.1517/17425247.4.4.427.
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013 Sep 17;109(6):1556–1561. doi:10.1038/bjc.2013.371.
   PubMed Web of Science ®Google Scholar
• Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2010 Feb 12;70(3):261–272. doi:10.2165/11532180-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 May 25;381(9880):1817–1826. doi:10.1016/S0140-6736(13)60313-X.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276. doi:10.1200/JCO.1999.17.1.268
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417–1423. doi:10.1182/blood-2004-08-3175.
   PubMed Web of Science ®Google Scholar
• Besada E. Rituximab og nøytropeni [Rituximab and neutropenia]. Tidsskr Nor Laegeforen. 2012 Oct 30;132(20):2259; author reply 2259. Norwegian. doi:10.4045/tidsskr.12.1147.
   PubMedGoogle Scholar
• Yelvington BJ. Subcutaneous Rituximab in follicular lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. J Adv Pract Oncol. 2018 Jul-Aug;9(5):530–534.
   PubMedGoogle Scholar